表紙
市場調查報告書

分子診斷照護現場 (POC)的全球市場 - 分析與預測:應用、技術、類型、終端用戶、15個國家的資料、競爭情形 (2019-2029年)

Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029

出版商 BIS Research Inc. 商品編碼 911559
出版日期 內容資訊 英文 238 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
分子診斷照護現場 (POC)的全球市場 - 分析與預測:應用、技術、類型、終端用戶、15個國家的資料、競爭情形 (2019-2029年) Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029
出版日期: 2019年09月16日內容資訊: 英文 238 Pages
簡介

全球分子診斷照護現場 (POC) 市場到2029年前預計將達到60億2,000萬美元的規模。

本報告提供全球分子診斷照護現場 (POC) 市場調查,市場概要,市場成長的各種影響因素分析,各市場區隔、各地區的分析與預測,及主要企業簡介等資訊彙整。

第1章 調查範圍、手法

第2章 市場概要

第3章 市場動態

  • 概要
  • 影響分析
  • 市場成長促進因素
  • 阻礙市場成長要素
  • 市場機會

第4章 競爭情形

  • 主要策略、發展

第5章 全球分子診斷照護現場 (POC) 市場:各產品

  • 概要
  • 化驗
  • 系統
  • 軟體

第6章 全球分子診斷照護現場 (POC) 市場:各用途

  • 概要
  • 感染疾病
    • 呼吸系統感染疾病
    • 醫療相關感染 (HAI)
    • 性感染疾病 (STI)
    • 腸胃感染疾病
  • 癌症
  • 產前檢查
  • 其他

第7章 全球分子診斷照護現場 (POC) 市場:各技術

  • 概要
  • 聚合酵素鏈鎖反應 (PCR)
    • 即時PCR (q-PCR)
    • 數位PCR (d-PCR)
  • 恆溫核酸增幅技術 (INAAT)
  • 其他

第8章 全球分子診斷照護現場 (POC) 市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (RoW)

第9章 全球分子診斷照護現場 (POC) 市場:各終端用戶

  • 概要
  • 醫院
  • 診所
  • 診斷中心
  • 其他終端用戶

第10章 產業考察

  • 市場佔有率分析
  • 成長佔有率分析

第11章 企業簡介

  • Abbott Laboratories
  • Abacus Diagnostica Oy
  • bioMerieux S.A.
  • Biocartis NV
  • Danaher Corporation
  • DiaSorin S.p.A
  • DxNA LLC
  • F. Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Hologic, Inc.
  • Mesa Biotech
  • Spartan Biosciences Inc.
  • QuantuMDx Group Ltd.
  • Quidel Corporation
  • QIAGEN N.V.
目錄
Product Code: BH164A

"Global Molecular Diagnostic Point of Care Market to Reach $6.02 Billion by 2029."

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global molecular diagnostic point of care market?
  • What are the factors resulting in the emerging trends within the global molecular diagnostic point of care market?
  • How is each segment of the global molecular diagnostic point of care market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in the global molecular diagnostic point of care market? What are the major segments of these applications?
  • Who are the key manufacturers the global molecular diagnostic point of care products, and what are their contributions?

Global Molecular Diagnostic Point of Care Market Forecast, 2019-2029

The global molecular diagnostic point of care industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029. The molecular diagnostic point of care market generated $1,689.6 million revenue in 2018, in terms of value.

The molecular diagnostic point of care market growth has been primarily attributed to the major drivers in this market such as highly increasing global prevalence of infectious diseases and various types of cancer, growing demand for non-invasive diagnostics, increase in adoption of personalized medicines on a global level, and significant external funding for executing research and development exercises. The challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers, and high capital requirement hampering the global reach.

Expert Quote

"There is no doubt that near-patient molecular testing represents the future of diagnosing infectious diseases, especially those like influenza that are highly transmissible."

Scope of the Market Intelligence on Global Molecular Diagnostic Point of Care Market

The molecular diagnostic point of care research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global molecular diagnostic point of care market.

Market Segmentation

The molecular diagnostic point of care market is segmented into infectious disease, oncology, prenatal testing and other applications, on the basis of application.

The molecular diagnostic point of care market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology and other methods, on the basis of technology.

The molecular diagnostic point of care market is segmented into assays, systems and software, on the basis of type.

The molecular diagnostic point of care market is segmented into hospitals, clinics, diagnostic centers, and other end-users, on the basis of end-user.

The molecular diagnostic point of care market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest-of-the-World, on the basis of geography.

Key Companies in the Molecular Diagnostic Point of Care Market:

The key manufacturers who have been contributing significantly to the molecular diagnostic point of care market include Hologic, Inc., Abbott Laboratories, bioMerieux S.A., QIAGEN N.V., Quidel Corporation, Biocartis NV, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche Ltd., Luminex Corporation, Mesa Biotech, QuantuMDx Group Ltd., Spartan Biosciences Inc., DxNA LLC, and Abacus Diagnostica Oy, among others.

Table of Contents

Executive Summary

1 Research Scope and Methodology

  • 1.1 Scope of the Study
  • 1.2 Research Methodology
  • 1.3 Data Sources
  • 1.4 Assumptions and Limitations
  • 1.5 Data and Prediction Modeling

2 Market Overview

  • 2.1 Market Available Molecular Diagnostics Point of Care Products
  • 2.2 Molecular Diagnostics Point of Care in Clinical Diagnostics
  • 2.3 Molecular Diagnostics Point of Care Technologies
  • 2.4 Regulatory Framework
    • 2.4.1 Legal Requirements and Framework in U.S.
    • 2.4.2 Legal Requirements and Framework in Europe
    • 2.4.3 Legal Requirements and Framework in Asia-Pacific
      • 2.4.3.1 China
      • 2.4.3.2 Japan

3 Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
    • 3.3.1 Growing Demand for Non-Invasive Diagnosis
    • 3.3.2 Increasing Prevalence of Infectious Diseases and Various Types of Cancer on a Global Level
    • 3.3.3 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
    • 3.3.4 Significant External Funding for Executing Research and Development Exercises
  • 3.4 Market Restraint
    • 3.4.1 Uncertain Reimbursement Scenario
    • 3.4.2 Lack of High Complexity Testing Centers
    • 3.4.3 High Capital Requirement Hampering the Expansion of Global Reach
  • 3.5 Market Opportunities
    • 3.5.1 Massive Scope for Adoption of Molecular Diagnostics-Based Point of Care Products in Emerging Nations
    • 3.5.2 Technological Advancements in Molecular Techniques and Diagnostic Tests
    • 3.5.3 Hybridization of Technologies

4 Competitive Landscape

  • 4.1 Key Strategies and Developments
    • 4.1.1 Approvals
    • 4.1.2 Synergistic Activities
    • 4.1.3 Product Launches and Enhancements
    • 4.1.4 Funding and Expansion Activities
    • 4.1.5 Acquisitions

5 Global Molecular Diagnostics Point of Care Market (by Product)

  • 5.1 Overview
  • 5.2 Assays
  • 5.3 Systems
  • 5.4 Software

6 Global Molecular Diagnostics Point of Care Market (by Application)

  • 6.1 Overview
  • 6.2 Infectious Disease
    • 6.2.1 Respiratory Infection
    • 6.2.2 Hospital Acquired Infections (HAI)
    • 6.2.3 Sexually Transmitted Infections (STIs)
    • 6.2.4 Gastro-Intestinal Infections
  • 6.3 Oncology
  • 6.4 Pre-natal Testing
  • 6.5 Others

7 Global Molecular Diagnostics Point of Care Market (by Technology)

  • 7.1 Overview
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Real-time PCR (q-PCR)
    • 7.2.2 Digital PCR (d-PCR)
  • 7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.4 Others

8 Global Molecular Diagnostics Point of Care Market (by Region)

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 The Netherlands
    • 8.3.7 Rest-of-Europe
  • 8.4 Asia-Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Singapore
    • 8.4.6 Rest-of-APAC
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest-of-Latin America
  • 8.6 Rest-of-the-World

9 Global Molecular Diagnostics Point of Care Market (by End-User)

  • 9.1 Overview
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Diagnostic Centers
  • 9.5 Other End-Users

10 Industry Insights

  • 10.1 Market Share Analysis
  • 10.2 Growth Share Analysis

11 Company Profiles

  • 11.1 Abbott Laboratories
    • 11.1.1 Company Overview
    • 11.1.2 Role of Abbott Laboratories in the Global Molecular Diagnostics Point of Care Market
    • 11.1.3 Financials
    • 11.1.4 Key Insights about Financial Health of the Company
    • 11.1.5 SWOT Analysis
  • 11.2 Abacus Diagnostica Oy
    • 11.2.1 Company Overview
    • 11.2.2 Role of Abacus Diagnostica Oy in the Global Molecular Diagnostics Point of Care Market
    • 11.2.3 SWOT Analysis
  • 11.3 bioMerieux S.A.
    • 11.3.1 Company Overview
    • 11.3.2 Role of bioMerieux S.A. in the Global Molecular Diagnostics Point of Care Market
    • 11.3.3 Financials
    • 11.3.4 Key Insights about Financial Health of the Company
    • 11.3.5 SWOT Analysis
  • 11.4 Biocartis NV
    • 11.4.1 Company Overview
    • 11.4.2 Role of Biocartis NV in the Global Molecular Diagnostics Point of Care Market
    • 11.4.3 Financials
    • 11.4.4 Key Insights about Financial Health of the Company
    • 11.4.5 SWOT Analysis
  • 11.5 Danaher Corporation
    • 11.5.1 Company Overview
    • 11.5.2 Role of Danaher Corporation in the Global Molecular Diagnostics Point of Care Market
    • 11.5.3 Financials
    • 11.5.4 Key Insights about Financial Health of the Company
    • 11.5.5 SWOT Analysis
  • 11.6 DiaSorin S.p.A
    • 11.6.1 Company Overview
    • 11.6.2 Role of DiaSorin S.p.A. in the Global Molecular Diagnostics Point of Care Market
    • 11.6.3 Financials
    • 11.6.4 Key Insights about Financial Health of the Company
    • 11.6.5 SWOT Analysis
  • 11.7 DxNA LLC
    • 11.7.1 Company Overview
    • 11.7.2 Role of DxNA LLC in the Point of Care Global Molecular Diagnostics Point of Care Market
    • 11.7.3 SWOT Analysis
  • 11.8 F. Hoffmann-La Roche Ltd
    • 11.8.1 Company Overview
    • 11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Point of Care Market
    • 11.8.3 Financials
    • 11.8.4 Key Insights about Financial Health of the Company
    • 11.8.5 SWOT Analysis
  • 11.9 Luminex Corporation
    • 11.9.1 Company Overview
    • 11.9.2 Role of Luminex Corporation in the Global Molecular Diagnostics Point of Care Market
    • 11.9.3 Financials
    • 11.9.4 Key Insights about Financial Health of the Company
    • 11.9.5 SWOT Analysis
  • 11.10 Hologic, Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Role of Hologic, Inc. in the Molecular Diagnostic Point of Care Market
    • 11.10.3 Financials
    • 11.10.4 Key Insights about Financial Health of the Company
    • 11.10.5 SWOT Analysis
  • 11.11 Mesa Biotech
    • 11.11.1 Company Overview
    • 11.11.2 Role of Mesa Biotech in the Molecular Diagnostics Point of Care Market
    • 11.11.3 SWOT Analysis
  • 11.12 Spartan Biosciences Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Role of Spartan Biosciences Inc. in the Molecular Diagnostics Point of Care Market
    • 11.12.3 SWOT Analysis
  • 11.13 QuantuMDx Group Ltd.
    • 11.13.1 Company Overview
    • 11.13.2 Role of QuantuMDx Group Ltd. In the Global Molecular Diagnostics Point of Care Market
    • 11.13.3 SWOT Analysis
  • 11.14 Quidel Corporation
    • 11.14.1 Company Overview
    • 11.14.2 Role of Quidel Corporation the Global Molecular Diagnostics Point of Care Market
    • 11.14.3 Financials
    • 11.14.4 Key Insights about Financial Health of the Company
    • 11.14.5 SWOT Analysis
  • 11.15 QIAGEN N.V.
    • 11.15.1 Company Overview
    • 11.15.2 Role of QIAGEN N.V. in the Global Molecular Diagnostics Point of Care Market
    • 11.15.3 Financials
    • 11.15.4 Key Insights about Financial Health of the Company
    • 11.15.5 SWOT Analysis

List of Tables

  • Table 2.1: Market Available Molecular Diagnostics Point of Care Products
  • Table 2.2: Classification rules of IVDs under the IVDR
  • Table 2.3: Registration Criteria for IVD Medical Devices as per the CFDA
  • Table 3.1: Impact Analysis of Market Drivers
  • Table 3.2: Impact Analysis of Market Restraints
  • Table 6.1: Global Estimates of New Cases of Curable STIs in 2016

List of Figures

  • Figure 1: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Point of Care Market
  • Figure 2: Global Molecular Diagnostics Point of Care Market Snapshot, 2018 and 2029
  • Figure 3: Dominating Segments of the Global Molecular Diagnostics Point of Care Market, 2019 and 2029
  • Figure 4: Key Strategies Incorporated by Stakeholders of Molecular Diagnostics Point of Care Market, to Sustain the Competition (from January 2016 to August 2019)
  • Figure 5: Global Molecular Diagnostics Point of Care Market Point of Care (by Product), 2018 and 2029
  • Figure 6: Global Molecular Diagnostics Point of Care Market (by Technology), 2018 and 2029
  • Figure 7: Global Molecular Diagnostics Point of Care Market (by End-User), 2018 and 2029
  • Figure 8: Global Molecular Diagnostics Point of Care Market (by Region) 2018 and 2029
  • Figure 1.1: Global Molecular Diagnostics Point-of-Care Market Segmentation
  • Figure 1.2: Global Molecular Diagnostics Point of Care Market Research Methodology
  • Figure 1.3: Primary Research
  • Figure 1.4: Secondary Research
  • Figure 1.5: Data Triangulation
  • Figure 1.6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 1.7: Top-Down Approach (Segment-Wise Analysis)
  • Figure 1.8: Assumptions and Limitations
  • Figure 1.9: Considered Factors for Data Prediction and Modeling
  • Figure 2.1: Characteristics of a Commercially Available Molecular Diagnostics Point of Care Products
  • Figure 2.2: Components Considered for Clinical Evidence as per the IVDR
  • Figure 3.1: Number of Deaths due to top 18 Infectious Diseases on a Global Scale, 2015
  • Figure 3.2: Number of Deaths due to Different Forms of Cancer, Million Units, 2018,
  • Figure 4.1: Share of Key Developments and Strategies, January 2016 - August 2019
  • Figure 4.2: Approvals Share (by Company), January 2016 - August 2019
  • Figure 4.3: Synergistic Activities Share (by Company), January 2016 - August 2019
  • Figure 4.4: Product Launches and Enhancements Share (by Company), January 2016 - August 2019
  • Figure 4.5: Funding Share (by Company), January 2016 - August 2019
  • Figure 4.6: Acquisitions Share (by Company), January 2016 - August 2019
  • Figure 5.1: Global Molecular Diagnostics Point of Care Market (by Product)
  • Figure 5.2: Global Molecular Diagnostics Point of Care Market (by Product), 2018-2029
  • Figure 5.3: General Workflow of a Molecular Diagnostics Point of Care Kit
  • Figure 5.4: Global Molecular Diagnostics Point of Care Market (Assays), 2018-2029
  • Figure 5.5: Global Molecular Diagnostics Point of Care Market (by Systems), 2018-2029
  • Figure 5.7: Aspects of Software Development
  • Figure 5.8: Global Molecular Diagnostics Point of Care Market (by Software), 2018-2029
  • Figure 6.1: Global Molecular Diagnostics Point of Care Market (by Application), 2018-2029
  • Figure 6.2: Global Molecular Diagnostics Point of Care Market (by Infectious Disease), 2018-2029
  • Figure 6.3: Global Molecular Diagnostics Point of Care Market (by Infectious Disease Type), 2018-2020
  • Figure 6.4: Global Molecular Diagnostics Point of Care Market (by Respiratory Infections), 2018-2029
  • Figure 6.5: Global Molecular Diagnostics Point of Care Market (by Hospital Acquired Infections), 2018-2029
  • Figure 6.6: Global Molecular Diagnostics Point of Care Market (by Sexually Transmitted Infections), 2018-2029
  • Figure 6.7: Global Molecular Diagnostics Point of Care Market (by Gastro-Intestinal Infections), 2018-2029
  • Figure 6.8: Global Molecular Diagnostics Point of Care Market (by Oncology), 2018-2029
  • Figure 6.9: Global Molecular Diagnostics Point of Care Market (by Pre-natal Testing), 2018-2029
  • Figure 6.10: Global Molecular Diagnostics Point of Care Market (by Other Applications), 2018-2029
  • Figure 7.1: Global Molecular Diagnostics Point of Care Market (by Technology), 2018-2029
  • Figure 7.2: Global Molecular Diagnostics Point of Care Market (by PCR), 2018-2029
  • Figure 7.3: Global Molecular Diagnostics Point of Care Market (by q-PCR), 2018-2029
  • Figure 7.4: Global Molecular Diagnostics Point of Care Market (by d-PCR), 2020-2029
  • Figure 7.5: Global Molecular Diagnostics Point of Care Market (by INAAT), 2018-2029
  • Figure 7.6: Global Molecular Diagnostics Point of Care Market (by Other Technologies), 2018-2029
  • Figure 8.1: Global Molecular Diagnostics Point of Care Market (by Region), 2018 and 2029
  • Figure 8.2: Global Molecular Diagnostics Point of Care Market Point of Care (by Region), 2018-2029
  • Figure 8.3: Global Molecular Diagnostics Point of Care Market Share (by Region), 2018
  • Figure 8.4: Global Molecular Diagnostics Point of Care Market Share (by Region), 2029
  • Figure 8.5: North America Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.6: North America Molecular Diagnostics Point of Care Market (by Country), 2018-2029
  • Figure 8.7: North America: Market Dynamics
  • Figure 8.8: The U.S. Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.9: Canada Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)
  • Figure 8.11: Europe Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.12: Europe: Market Dynamics
  • Figure 8.13: Europe Molecular Diagnostics Point of Care Market (by Country), 2018-2029
  • Figure 8.14: Germany Point of Care Molecular Diagnostics Market, 2018-2029
  • Figure 8.15: U.K. Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.16: France Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.17: Italy Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8 18: Spain Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.19: The Netherlands Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.20: Rest-of-Europe Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.21: Asia-Pacific Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.22: APAC: Market Dynamics
  • Figure 8.23: APAC Global Molecular Diagnostics Point of Care Market (by Country), 2018-2029
  • Figure 8.24: China Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.25: Japan Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.26: India Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.27: Australia Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.28: Singapore Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.29: RoAPAC Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.30: Latin America Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.31: Latin America: Market Dynamics
  • Figure 8.32: Latin America Molecular Diagnostics Point of Care Market (by Country), 2018-2029
  • Figure 8.33: Brazil Molecular Diagnostics Point of Care Market 2018-2029
  • Figure 8.34: Mexico Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.35: Rest-of-Latin America Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 8.36: RoW Molecular Diagnostics Point of Care Market, 2018-2029
  • Figure 9.1: Global Molecular Diagnostics Point of Care Market (by End-User)
  • Figure 9.2: Global Molecular Diagnostics Point of Care Market (by End User), 2018-2029
  • Figure 9.3: Global Molecular Diagnostics Point of Care Market (by Hospitals), 2018-2029
  • Figure 9.4: Global Molecular Diagnostics Point of Care Market (by Clinics), 2018-2029
  • Figure 9.5: Global Molecular Diagnostics Point of Care Market (Diagnostic Centers), 2018-2029
  • Figure 9.6: Global Molecular Diagnostics Point of Care Market (by Other End-Users), 2018-2029
  • Figure 10.1: Market Share Analysis for the Global Molecular Diagnostics Point of Care Market, 2018
  • Figure 10.2: Growth Share Matrix for Molecular Diagnostics Point of Care Market (by Company), 2018
  • Figure 11.1: Total Number of Companies Profiled
  • Figure 11.2: Abbott Laboratories: Overall Product Portfolio
  • Figure 11.3: Abbott Laboratories: Overall Financials, 2016-2018
  • Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
  • Figure 11.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
  • Figure 11.6: Abbott Laboratories: Revenue (by Region), 2016-2018
  • Figure 11.7: Abbott Laboratories: R&D Expenditure, 2016-2018
  • Figure 11.8: Abbott Laboratories: SWOT Analysis
  • Figure 11.9: Abacus Diagnostica Oy.: Overall Product Portfolio (Available from FY2019)
  • Figure 11.10: Abacus Diagnostica Oy: SWOT Analysis
  • Figure 11.11: bioMerieux S.A.: Overall Product Portfolio
  • Figure 11.12: bioMerieux S.A.: Overall Financials, 2016-2018
  • Figure 11.13: bioMerieux S.A.: Revenue (by Segment), 2016-2018
  • Figure 11.14: bioMerieux S.A.: Revenue (by Region), 2016-2018
  • Figure 11.15: bioMerieux S.A.: R&D Expenditure, 2016-2018
  • Figure 11.16: bioMerieux S.A.: SWOT Analysis
  • Figure 11.17: Biocartis NV: Overall Product Portfolio
  • Figure 11.18: Biocartis NV: Overall Financials, 2016-2018
  • Figure 11.19: Biocartis NV: R&D Expenditure, 2016-2018
  • Figure 11.20: Biocartis NV: SWOT Analysis
  • Figure 11.21: Danaher Corporation: Molecular Diagnostics Point of Care Product Portfolio
  • Figure 11.22: Danaher Corporation: Overall Financials, 2016-2018
  • Figure 11.23: Danaher Corporation: Revenue (by Business Segment), 2016-2018
  • Figure 11.24: Danaher Corporation: Revenue (by Region), 2016-2018
  • Figure 11.25: Danaher Corporation: R&D Expenditure, 2016-2018
  • Figure 11.26: Danaher Corporation: SWOT Analysis
  • Figure 11.27: DiaSorin S.p.A.: Overall Financials, 2016-2018
  • Figure 11.28: DiaSorin S.p.A.: Revenue (by Segment), 2016-2018
  • Figure 11.29: DiaSorin S.p.A.: By Region, 2016-2018
  • Figure 11.30: DiaSorin S.p.A: R&D Expenditure, 2016-2018
  • Figure 11.31: DiaSorin S.p.A: SWOT Analysis
  • Figure 11.32: DxNA LLC.: Overall Product Portfolio (Available from FY2019)
  • Figure 11.33: DxNA LLC Group Ltd.: SWOT Analysis
  • Figure 11.34: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 11.35: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 11.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 11.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
  • Figure 11.38: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
  • Figure 11.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
  • Figure 11.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 11.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 11.42: Luminex Corporation: Overall Product Portfolio
  • Figure 11.43: Luminex Corporation: Overall Financials, 2016-2018
  • Figure 11.44: Luminex Corporation: Revenue (by Segment), 2016-2018
  • Figure 11.45: Luminex Corporation: Revenue (by Region), 2016-2018
  • Figure 11.46: Luminex Corporation: R&D Expenditure, 2016-2018
  • Figure 11.47: Luminex Corporation: SWOT Analysis
  • Figure 11.48: Hologic, Inc.: Overall Product Portfolio
  • Figure 11.49: Hologic, Inc.: Overall Financials, 2016-2018
  • Figure 11.50: Hologic, Inc.: Revenue (by Segment), 2016-2018
  • Figure 11.51: Hologic, Inc.: Revenue (by Region), 2016-2018
  • Figure 11.52: Hologic, Inc.: R&D Expenditure, 2016-2018
  • Figure 11.53: Hologic, Inc.: SWOT Analysis
  • Figure 11.54: Mesa Biotech: Overall Product Portfolio (Available from FY2019)
  • Figure 11.55: Mesa Biotech: SWOT Analysis
  • Figure 11.56: Spartan Biosciences Inc.: Overall Product Portfolio (Available from FY2019)
  • Figure 11.57: Spartan Biosciences, Inc.: SWOT Analysis
  • Figure 11.58: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)
  • Figure 11.59: QuantuMDx Group Ltd.: SWOT Analysis
  • Figure 11.60: Quidel Corporation Ltd.: Overall Product Portfolio (Available from FY2019)
  • Figure 11.61: Quidel Corporation: Overall Financials, 2016-2018
  • Figure 11.62: Quidel Corporation: Revenue (by Segment), 2016-2018
  • Figure 11.63: Quidel Corporation: Revenue (by Region), 2016-2018
  • Figure 11.64: Quidel Corporation: R&D Expenditure, 2016-2018
  • Figure 11.65: Quidel Corporation: SWOT Analysis
  • Figure 11.66: QIAGEN N.V.: Overall Product Portfolio
  • Figure 11.67: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 11.68: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 11.69: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 11.70: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 11.71: QIAGEN N.V.: SWOT Analysis
Back to Top